Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation
- PMID: 6863539
- PMCID: PMC370374
- DOI: 10.1172/jci110924
Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation
Abstract
To investigate mechanisms that control large variations among normal uninduced subjects in the elimination of the model compound antipyrine (AP) and other drugs, AP was administered to 144 subjects (83 unrelated adults and 61 members of 13 families). Thereafter, at regular intervals for 72 h, the urine of each subject was collected and concentrations of AP and its three main metabolites measured. From these urinary concentrations, rate constants for formation of each AP metabolite were calculated. Trimodal curves were observed when values for each AP rate constant were plotted in 83 unrelated subjects; probit plots of these values showed inflections at the two antimodes of each trimodal distribution. All members of our 13 families were assigned one of three phenotypes determined by where their AP metabolite rate constant placed them in the trimodal distributions derived from the 83 unrelated subjects. In each family, pedigree analysis to identify the mode of transmission of these three phenotypes was consistent with their monogenic control. These results provide evidence for a new polymorphism of drug oxidation in man.
Similar articles
-
A new polymorphism of hepatic drug oxidation in humans: family studies of antipyrine metabolites.Fed Proc. 1984 May 15;43(8):2342-7. Fed Proc. 1984. PMID: 6714443
-
Polymorphism of theophylline metabolism in man.J Clin Invest. 1985 May;75(5):1415-25. doi: 10.1172/JCI111843. J Clin Invest. 1985. PMID: 4039734 Free PMC article.
-
A new polymorphism of hepatic drug oxidation in man: family studies on rates of formation of antipyrine metabolites.Biochem Soc Trans. 1984 Feb;12(1):74-8. doi: 10.1042/bst0120074. Biochem Soc Trans. 1984. PMID: 6705993 No abstract available.
-
Assessment of methods to identify sources of interindividual pharmacokinetic variations.Clin Pharmacokinet. 1983 Sep-Oct;8(5):378-409. doi: 10.2165/00003088-198308050-00002. Clin Pharmacokinet. 1983. PMID: 6194927 Review.
-
[Metabolism of antipyrine in man].Pathol Biol (Paris). 1985 Sep;33(7):777-80. Pathol Biol (Paris). 1985. PMID: 3909077 Review. French.
Cited by
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
-
Simplified approaches to the determination of antipyrine pharmacokinetic parameters.Br J Clin Pharmacol. 1988 Jun;25(6):695-9. doi: 10.1111/j.1365-2125.1988.tb05255.x. Br J Clin Pharmacol. 1988. PMID: 3203041 Free PMC article.
-
Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.Clin Pharmacokinet. 1991 Jan;20(1):50-65. doi: 10.2165/00003088-199120010-00004. Clin Pharmacokinet. 1991. PMID: 2029802 Review.
-
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.Eur J Clin Pharmacol. 1984;26(6):753-9. doi: 10.1007/BF00541938. Eur J Clin Pharmacol. 1984. PMID: 6489416
-
Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine.Eur J Clin Pharmacol. 1988;35(4):413-7. doi: 10.1007/BF00561374. Eur J Clin Pharmacol. 1988. PMID: 3197750
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases